Kenvue Inc (KVUE) Stock Price, Quote & News

Company Profile

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and bod...

Industry: Household & Personal Products

Sector: Consumer Defensive

Phone: 908 874 1200

Website: www.kenvue.com

Address:

1 Kenvue Way, Summit, United States

OpenOutcrier Sep. 14 at 12:11 PM

$KMB $KVUE Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say - Reuters https://ooc.bz/l/114017

0 · Reply

peloswing Sep. 11 at 5:32 PM

$KVUE massive symmetrical triangle on the daily chart. Sitting on diagonal + horizontal support here + 200 DMA. - Kenvue, the maker of Tylenol, along with several retailers and pharmacy chains, has asked a federal appeals court to reconsider its decision to revive more than 500 lawsuits alleging a link between Tylenol use and autism 💊

0 · Reply

SuperGreenToday Sep. 11 at 3:38 AM

$KVUE Share Price: $17.78 Contract Selected: Oct 02, 2026 $20 Calls Buy Zone: $0.12 – $0.15 Target Zone: $0.20 – $0.25 Potential Upside: 55% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TalkMarkets Sep. 9 at 4:51 PM

My Favorite Consumer Staples Play Right Now $KMB $KVUE Also Mentions: $K $BUD https://talkmarkets.com/article/my-favorite-consumer-staples-play-right-now-1788970940

0 · Reply

SuperGreenToday Sep. 7 at 10:28 PM

$KVUE Share Price: $18.72 Contract Selected: Oct 02, 2026 $20 Calls Buy Zone: $0.08 – $0.10 Target Zone: $0.15 – $0.19 Potential Upside: 70% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZOO_LANDER Sep. 7 at 1:03 AM

$KVUE THIS IS A BOT. LOOK AT IT'S POSTS....ZZZZZZZXXXX

0 · Reply

MollyJones567 Sep. 6 at 9:02 PM

$KVUE quietly seeing some institutional attention lately. Not the flashiest name on the board but the accumulation pattern is worth watching. Consumer staples names like this tend to attract steady hands over hype chasers. Keeping this one on the radar.

0 · Reply

SuperGreenToday Sep. 4 at 9:16 PM

$KVUE Share Price: $18.72 Contract Selected: Sep 25, 2026 $20 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 71% ROI Time to Expiration: 20 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TwelveEggsInOneBasket Sep. 4 at 7:16 PM

$KVUE it should dip under 18 given KMBs current SP.

0 · Reply

SuperGreenToday Sep. 3 at 8:34 PM

$KVUE Share Price: $18.92 Contract Selected: Sep 25, 2026 $20 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 71% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Kimberly-Clark readying asset sales for Kenvue deal EU approval, Reuters says

KMB

Sep 14, 2026, 6:56 AM EDT - 1 hour ago

Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say

KMB

Sep 12, 2026, 8:06 AM EDT - 2 days ago

My Favorite Consumer Staples Play Right Now

KMB

Sep 10, 2026, 6:45 AM EDT - 4 days ago

Kenvue Declares Quarterly Cash Dividend

Sep 9, 2026, 12:02 AM EDT - 5 days ago

Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters

Sep 1, 2026, 9:23 PM EDT - 12 days ago

Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment

KMB

2026-08-28T10:11:03.000Z - 17 days ago

Kimberly-Clark seeking EU approval for $40B Kenvue takeover, Reuters reports

KMB

Aug 28, 2026, 3:54 AM EDT - 17 days ago

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

KMB

Aug 13, 2026, 9:25 AM EDT - 4 weeks ago

Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel

KMB

2026-08-11T12:46:05.000Z - 4 weeks ago

Kenvue price target lowered to $19 from $20 at UBS

Aug 6, 2026, 9:30 AM EDT - 5 weeks ago

Kenvue Quarterly report: Q2 2026

Aug 6, 2026, 9:30 AM EDT - 5 weeks ago

Kenvue Earnings release: Q2 2026

Aug 6, 2026, 7:47 AM EDT - 5 weeks ago

Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Aug 6, 2026, 7:38 AM EDT - 5 weeks ago

Kenvue Posts Higher Profit, Sales as Turnaround Continues

2026-08-06T10:53:31.000Z - 5 weeks ago

Kenvue reports Q2 adjusted EPS 31c, consensus 32c

Aug 6, 2026, 6:45 AM EDT - 5 weeks ago

Kenvue Reports Second Quarter 2026 Results

Jul 30, 2026, 4:20 PM EDT - 6 weeks ago

Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US

COST CVS GSK HLN PG TGT WMT

2026-07-29T10:50:31.000Z - 6 weeks ago

Kenvue raises quarterly dividend 1.2% to 21c per share

Jul 29, 2026, 6:45 AM EDT - 6 weeks ago

Kenvue Increases Quarterly Cash Dividend

2026-07-24T18:10:13.000Z - 7 weeks ago

Kenvue confirms FDA approves Tylenol with Naproxen OTC combination

Jul 24, 2026, 12:00 PM EDT - 7 weeks ago

US FDA approves over-the-counter Tylenol combination pill for pain relief

Jul 23, 2026, 6:45 AM EDT - 7 weeks ago

Kenvue to Announce Second Quarter 2026 Results on August 6, 2026

2026-07-21T10:05:54.000Z - 7 weeks ago

Kenvue price target raised to $19 from $18 at Barclays

2026-07-16T12:16:29.000Z - 2 months ago

Kenvue price target raised to $20 from $18 at UBS

2026-07-13T15:30:10.000Z - 2 months ago

Appeals court revives autism suits against Kenvue’s Tylenol, Bloomberg says

2026-07-13T15:25:13.000Z - 2 months ago

Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says

Jul 13, 2026, 10:54 AM EDT - 2 months ago

US appeals court revives private lawsuits linking Tylenol to autism, ADHD

2026-06-17T10:40:09.000Z - 2 months ago

Kimberly-Clark price target raised to $121 from $115 at Piper Sandler

KMB

Jun 3, 2026, 8:10 AM EDT - 3 months ago

Wall Street hated these 15 stocks. Then their earnings proved the analysts wrong.

AES ARW BAX EXP EXPD HPQ IESC

May 21, 2026, 9:00 AM EDT - 3 months ago

Kenvue Transcript: AGM 2026

May 7, 2026, 9:30 AM EDT - 4 months ago

Kenvue Earnings release: Q1 2026

May 7, 2026, 9:30 AM EDT - 4 months ago

Kenvue Quarterly report: Q1 2026

May 7, 2026, 7:15 AM EDT - 4 months ago

Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark

KMB

May 7, 2026, 6:30 AM EDT - 4 months ago

Kenvue Reports First Quarter 2026 Results

Apr 26, 2026, 9:40 AM EDT - 4 months ago

This 5-Stock “Super Staples” Portfolio Yields Up To 11.3%

CAG CALM FLO KMB NOMD

Apr 23, 2026, 4:32 PM EDT - 4 months ago

Kenvue to Announce First Quarter 2026 Results on May 7, 2026

Apr 15, 2026, 10:01 AM EDT - 5 months ago

Kimberly-Clark Details Structure, Leadership Team Following Kenvue Deal

KMB

Apr 15, 2026, 9:52 AM EDT - 5 months ago

Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal

KMB

Apr 15, 2026, 8:55 AM EDT - 5 months ago

Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership

KMB

Apr 13, 2026, 2:09 PM EDT - 5 months ago

Tylenol in pregnancy not linked with autism, Danish study finds

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Kenvue Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Kenvue Proxy statement: Proxy filing

Mar 6, 2026, 12:43 PM EST - 6 months ago

Tylenol use among women dropped after Trump tied it to autism

Feb 26, 2026, 11:14 AM EST - 6 months ago

Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol

Feb 17, 2026, 5:50 PM EST - 6 months ago

Kenvue to Cut 3.5% of Workforce Ahead of Kimberly-Clark Deal

Feb 17, 2026, 5:42 PM EST - 6 months ago

Kenvue beats quarterly estimates, announces job cuts amid Kimberly-Clark acquisition

KMB

Feb 17, 2026, 4:45 PM EST - 6 months ago

Kenvue Reports Fourth Quarter and Full Year 2025 Results

Feb 17, 2026, 4:00 PM EST - 6 months ago

Kenvue Annual report: Q4 2025

Feb 17, 2026, 4:00 PM EST - 6 months ago

Kenvue Earnings release: Q4 2025

Feb 4, 2026, 6:45 AM EST - 7 months ago

Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

OpenOutcrier Sep. 14 at 12:11 PM

$KMB $KVUE Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say - Reuters https://ooc.bz/l/114017

0 · Reply

peloswing Sep. 11 at 5:32 PM

0 · Reply

SuperGreenToday Sep. 11 at 3:38 AM

0 · Reply

TalkMarkets Sep. 9 at 4:51 PM

My Favorite Consumer Staples Play Right Now $KMB $KVUE Also Mentions: $K $BUD https://talkmarkets.com/article/my-favorite-consumer-staples-play-right-now-1788970940

0 · Reply

SuperGreenToday Sep. 7 at 10:28 PM

0 · Reply

ZOO_LANDER Sep. 7 at 1:03 AM

$KVUE THIS IS A BOT. LOOK AT IT'S POSTS....ZZZZZZZXXXX

0 · Reply

MollyJones567 Sep. 6 at 9:02 PM

0 · Reply

SuperGreenToday Sep. 4 at 9:16 PM

0 · Reply

TwelveEggsInOneBasket Sep. 4 at 7:16 PM

$KVUE it should dip under 18 given KMBs current SP.

0 · Reply

SuperGreenToday Sep. 3 at 8:34 PM

0 · Reply

AStrokeOfLuck Sep. 2 at 12:38 PM

$KMB $KVUE

1 · Reply

SuperGreenToday Sep. 2 at 12:13 AM

$KVUE Share Price: $18.74 Contract Selected: Sep 25, 2026 $20 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.13 – $0.15 Potential Upside: 56% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Sep. 1 at 12:31 AM

$KVUE Share Price: $18.89 Contract Selected: Sep 25, 2026 $20 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.12 – $0.15 Potential Upside: 53% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

RosarioKopicko693 Aug. 27 at 7:22 AM

$P $FMX $KVUE $CCL $KMB Pandora benefits from digital audio engagement and advertising, FEMSA benefits from consumer and beverage demand, Kenvue remains focused on consumer-health brands, Carnival benefits from resilient cruise demand, and Kimberly-Clark benefits from staple-product demand and pricing. I'm watching ad growth, Latin American consumption, healthcare brands, cruise bookings, and input costs.

0 · Reply

CapitalMonk Aug. 20 at 1:15 AM

$KVUE Price: $19.13 (+1.76%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.37% RSI: 50.6 | Momentum: Moderate Volume: +15.9% vs avg Volatility: 1.47% Support: $18.48 | Resistance: $19.83 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

heikoscreens Aug. 19 at 6:57 PM

Congress filings just updated on my House Trades scanner: Rep. Kevin Hern disclosed sells in $CMCSA, $EL, $KVUE, $MDLZ — all around 8,000 USD, all dated Aug 5, reported this week (that reporting lag is normal, nothing shady). Small size, but four names sold same day is a pattern. Anyone track these filings regularly?

0 · Reply

TragicRain Aug. 19 at 5:22 PM

$KVUE Essity Strikes Agreement To Acquire Kenvue's Feminine Care Operations In Brazil For $284M

0 · Reply

ValuationPolice91 Aug. 17 at 10:25 PM

$KVUE this brand owns Neutrogena. Which dropped Hayden P for suffering with depression $SPY

1 · Reply

Spotterus Aug. 13 at 7:14 PM

$KVUE have a 1000 kvue shares at 15.98. I have no interest in kmb, so if the merger hits i get $3500 and 146 kmb shares. For me it looks better to sell kvue above $19.50 and not dealing with the merger and having to sell 146 kmb shares for ???. again i have zero interest in kmb.

0 · Reply

Snipertradesexpert Aug. 13 at 3:02 PM

$KVUE 🧴 $19.5 14 AUG 26 (W) CALL 100 $0.13 ➡️ $0.06 ❎ 53% LOSS! ❌

0 · Reply

LUXtrades0 Aug. 13 at 2:53 PM

$KVUE 🧴 $19.5 14 AUG 26 (W) CALL 100 $0.13 ➡️ $0.06 ❎ 53% LOSS! ❌

0 · Reply

Market Cap	34.15B
Revenue (ttm)	15.12B
Net Income (ttm)	1.47B
EPS (ttm)	N/A
PE Ratio	15.07
Forward PE	15.55
Profit Margin	9.72%
Debt to Equity Ratio	0.67

Volume	47,161,100
Avg Vol	21,476,137
Day's Range	N/A - N/A
Shares Out	1.92B
Stochastic %K	11%
Beta	0.46
Analysts	Sell
Price Target	$19.33